Candel Q2 net loss $38.9M; BLA for prostate cancer drug planned Q4 2026

Candel Therapeutics, Inc.

Net loss $38.9M in Q2 2026 vs $4.8M in Q2 2025, including $12.2M net other expense from warrant liabilities.
R&D expenses $19.8M (vs $7.0M YoY); G&A $6.9M (vs $4.2M YoY).
Cash and equivalents $201.6M as of June 30, 2026; expected to fund operations into Q1 2028.
BLA submission for aglatimagene in localized prostate cancer planned Q4 2026; potential U.S. launch in 2027 if approved.
Phase 3 data in The Lancet Oncology showed 39% improvement in PCa-specific DFS at 58 months; Mark Sims appointed CCO.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.